Havn Life Sciences Inc. (HAVLF)

[DGTrader55]

HUGE NEWS

Havn Life Sciences hits major milestone with research partner,
Complex Biotech Discovery Ventures
Havn Research signs contract with CBDV, located at The University of British Columbia’s Vancouver
campus, to begin Health Canada approved research to analyze psilocybin under Havn Life’s
Section 56 exemption.
The results of the analysis will allow Havn Life to begin the development of a library of psilocybin
compounds.
December 16, 2020
Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn
Life”), a biotechnology company pursuing standardized extraction of psychoactive
compounds, the development of natural healthcare products, and innovative mental health
treatment to support brain health and enhance the capabilities of the mind, is pleased to
announce it is partnering with Complex Biotech Discovery Ventures (CBDV) to begin Health
Canada approved analysis of psilocybin under Havn Life’s section 56 exemption.
CBDV is a licensed cannabis research and development firm focusing on extraction,
optimization, analytical testing and chemical process development based at the Vancouver
Campus at the University of British Columbia.
Havn Life will be conducting a comparative study at CBDV lab that will test various
methodologies of extraction to assess the merits and drawbacks of each. The results will be
used to help develop Havn Life’s methodology for analyzing psilocybin mushrooms and
products.
In addition, Havn Life will work towards the development of the very first library of psilocybin
compounds and lay the foundation for future development of proprietary extraction methods.
“Analysis is the foundation of Havn Life’s research objectives, enabling quality assurance and
rapid development of our extraction techniques and methodologies,” says Alexzander
Samuelsson, Chief Research Officer for Havn Life. “By building a foundational understanding
of current methods used today, we will leverage known research to develop an optimal process
for the standardization of psilocybin extraction. This ultimately allows Havn to supply academic
researchers with high quality, standardized compounds.”
The study will provide Havn Life with the tools and an understanding of method development
for specific compounds (psilocybin) that can later be used to develop a library of compounds
for researchers.
“It will also mean that Havn Life can rapidly develop our proprietary extraction methods in?house more quickly by eliminating the need to send compounds to third-party labs,” explains Samuelsson. “This makes a huge difference between discovery and optimization to scaling
processes, allowing Havn Life to expedite our internal development process.”
The work is enabled by Havn Life’s Section 56 exemption, granted by Health Canada, pursuant
to which the company has the ability to possess certain amounts of pure psilocybin for scientific
purposes, specifically for the research and development of quality control methods.
The Section 56 exemption also provides Havn Life with unique access to handle psilocybin and
develop in-house analytical protocols. This will provide experience in quantitatively analyzing
psilocybin as a cornerstone of quality control and quality assurance for process development
and product reliability

https://webfiles.thecse.com/Havn_NR_-_Dec_15_-_CBDV.pdf?vX7_Bn75CFlpXX7uw0vFmQXQB0ue6DXx